

Roche Pharma Day 2020

14 September 2020



Roche Pharma Day 2020

Welcome

Karl Mahler | Head of Investor Relations and Roche Group Planning

Agenda



Welcome

Karl Mahler, Head of Investor Relations and Roche Group Planning

Pharma Strategy: Sustainable growth, more patient benefits, and less cost to society

Bill Anderson, CEO Roche Pharmaceuticals

Commercial Opportunities

Teresa Graham, Head Pharma Global Product Strategy (GPS)

Short break

Late Stage Pipeline Oncology & Non-malignant Hematology

Levi Garraway, Chief Medical Officer and Head Global Product Development

Late Stage Pipeline Neuroscience

Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development

Late Stage Pipeline Immunology & Ophthalmology

Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) GPS

Infectious Diseases: A close look at our HBV pipeline

John Young, Global Head of Infectious Diseases, pRED

Late Stage Infectious Diseases: Influenza & SARS-CoV-2

Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) GPS

Q&A

36 Breakthrough Therapy Designations received since 2013

Reflecting the quality of our research

Year	Molecule	Indication
2020	<i>mosunetuzumab</i>	<i>3L+ FL</i>
	<i>Tecentriq</i>	<i>unresectable or metastatic ASPS</i>
	<i>Esbriet</i>	<i>uILD</i>
2019	<i>Gavreto</i>	<i>RET fusion-positive NSCLC</i>
	<i>Gavreto</i>	<i>RET mutation-positive MTC</i>
	<i>Cotellic</i>	<i>Histiocytic neoplasms</i>
	<i>Gazyva</i>	<i>Lupus nephritis</i>
	<i>rhPentraxin-2 (PRM-151)</i>	<i>IPF</i>
	<i>Venclexta + Gazyva</i>	<i>1L unfit CLL</i>
	<i>Kadcyla</i>	<i>Adjuvant HER2+ BC</i>
2018	<i>SPK-8011</i>	<i>Hemophilia A</i>
	<i>Enspryng</i>	<i>NMOSD</i>
	<i>Xolair</i>	<i>Food allergies</i>
	<i>Tecentriq + Avastin</i>	<i>1L HCC</i>
	<i>Hemlibra</i>	<i>Hemophilia A non-inhibitors</i>
	<i>Rozlytrek</i>	<i>NTRK+ solid tumors</i>
2017	<i>Polivy + BR</i>	<i>R/R DLBCL</i>
	<i>Venclexta + LDAC</i>	<i>1L unfit AML</i>
	<i>Zelboraf</i>	<i>BRAF-mutated ECD</i>
	<i>Rituxan</i>	<i>Pemphigus vulgaris</i>

Doing now what patients need next